Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib plus azacitidine in newly diagnosed elderly AITL
ChiCTR2600130794Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib and azacitidine in angioimmunoblastic T-cell lymphoma (AITL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Objective response rate and Progression-free survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
golidocitinibazacitidine
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on ChiCTR2600130794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130794.